Literature DB >> 22627795

Clinical stroke penumbra: use of National Institutes of Health stroke scale as a surrogate for CT perfusion in patient triage for intra-arterial middle cerebral artery stroke therapy.

J L Boxerman1, M V Jayaraman, W A Mehan, J M Rogg, R A Haas.   

Abstract

BACKGROUND AND
PURPOSE: CTP may help triage acute stroke patients for IAT, but requires additional contrast agent, radiation, and imaging time. Our aim was to determine whether clinical examination (NIHSS) with NCCT and CTA can substitute for CTP without significantly affecting IAT triage of patients with acute MCA stroke.
MATERIALS AND METHODS: We reviewed NCCT, CTA, and CTP imaging performed within 8 hours of symptom onset in 36 patients presenting with MCA territory stroke (September 2007-October 2009). Two neuroradiologists reviewed, independently and by consensus, NCCT, CTA, and CTP (CTP group), and 2 different neuroradiologists blinded to CTP reviewed NCCT, CTA, and NIHSS (stroke scale group) to determine IAT eligibility: M1 or proximal M2 occlusion; infarct core <1/3 MCA territory; and ischemic penumbra >20% infarct core. The stroke scale group estimated infarct core from NCCT and CTA source images and ischemic penumbra from core size relative to NIHSS score and re-evaluated patients after unblinding to CTP. We computed intragroup and intergroup κ scores for IAT treatment recommendation and used the McNemar test to determine whether CTP significantly affected the stroke scale group's decisions.
RESULTS: IAT was recommended in 16/36 (44%) and 17/36 (47%) patients by the CTP and stroke scale groups, respectively, with intragroup κ scores of 0.78 ± 0.11 versus 0.83 ± 0.09. The intergroup κ score was 0.83 ± 0.09. When unblinded to CTP, the stroke scale group revised 2/36 (5.6%) decisions, which was insignificant (P = .48, McNemar test).
CONCLUSIONS: NIHSS interpreted with NCCT and CTA may be an effective substitute for CTP-derived measures in the IAT triage of patients with acute MCA stroke. Replacing CTP may potentially reduce radiation and contrast dose and time to treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22627795      PMCID: PMC7964623          DOI: 10.3174/ajnr.A3102

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  36 in total

1.  Using the baseline CT scan to select acute stroke patients for IV-IA therapy.

Authors:  M D Hill; A M Demchuk; T A Tomsick; Y Y Palesch; J P Broderick
Journal:  AJNR Am J Neuroradiol       Date:  2006-09       Impact factor: 3.825

2.  The Interventional Management of Stroke (IMS) II Study.

Authors: 
Journal:  Stroke       Date:  2007-05-24       Impact factor: 7.914

3.  CT cerebral blood flow maps optimally correlate with admission diffusion-weighted imaging in acute stroke but thresholds vary by postprocessing platform.

Authors:  Shahmir Kamalian; Shervin Kamalian; Matthew B Maas; Greg V Goldmacher; Seyedmehdi Payabvash; Adnan Akbar; Pamela W Schaefer; Karen L Furie; R Gilberto Gonzalez; Michael H Lev
Journal:  Stroke       Date:  2011-05-05       Impact factor: 7.914

4.  ASPECT scoring to estimate >1/3 middle cerebral artery territory infarction.

Authors:  Bart M Demaerschalk; Brian Silver; Edward Wong; Jose G Merino; Arturo Tamayo; Vladimir Hachinski
Journal:  Can J Neurol Sci       Date:  2006-05       Impact factor: 2.104

5.  Low cerebral blood volume is predictive of diffusion restriction only in hyperacute stroke.

Authors:  Michael Knash; Adrian Tsang; Bilal Hameed; Monica Saini; Thomas Jeerakathil; Christian Beaulieu; Derek Emery; Kenneth Butcher
Journal:  Stroke       Date:  2010-11-04       Impact factor: 7.914

6.  Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort.

Authors:  M Fiorelli; S Bastianello; R von Kummer; G J del Zoppo; V Larrue; E Lesaffre; A P Ringleb; S Lorenzano; C Manelfe; L Bozzao
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

7.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

8.  Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke.

Authors:  Max Wintermark; Adam E Flanders; Birgitta Velthuis; Reto Meuli; Maarten van Leeuwen; Dorit Goldsher; Carissa Pineda; Joaquin Serena; Irene van der Schaaf; Annet Waaijer; James Anderson; Gary Nesbit; Igal Gabriely; Victoria Medina; Ana Quiles; Scott Pohlman; Marcel Quist; Pierre Schnyder; Julien Bogousslavsky; William P Dillon; Salvador Pedraza
Journal:  Stroke       Date:  2006-03-02       Impact factor: 7.914

9.  Quantitative assessment of core/penumbra mismatch in acute stroke: CT and MR perfusion imaging are strongly correlated when sufficient brain volume is imaged.

Authors:  Pamela W Schaefer; Elizabeth R Barak; Shahmir Kamalian; Leila Rezai Gharai; Lee Schwamm; Ramon Gilberto Gonzalez; Michael H Lev
Journal:  Stroke       Date:  2008-08-21       Impact factor: 7.914

10.  Clinical-diffusion mismatch defined by NIHSS and ASPECTS in non-lacunar anterior circulation infarction.

Authors:  H Tei; S Uchiyama; T Usui
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

View more
  3 in total

Review 1.  Intra-arterial Stroke Management.

Authors:  Ethan A Prince; Sun Ho Ahn; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

2.  Interventional management of acute ischemic stroke: a systematic review.

Authors:  J Scott Pannell; David R Santiago-Dieppa; Alexander A Khalessi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-08

Review 3.  Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset.

Authors:  Mark R Etherton; Andrew D Barreto; Lee H Schwamm; Ona Wu
Journal:  Front Neurol       Date:  2018-05-15       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.